In the New England Journal of Medicine, Wang et al. report favorable ZUMA-2 trial results of CAR T cells for patients with relapsed and refractory mantle cell lymphoma following prior failed Bruton’s tyrosine kinase inhibitor therapy, with an overall response rate of 93% and an expected safety profile.

中文翻译：

---

用于套细胞淋巴瘤的CAR T细胞：是时候对甲板进行改组了吗？

在《新英格兰医学杂志》上，Wang等人。报道了先前布鲁顿酪氨酸激酶抑制剂治疗失败后复发和难治性套细胞淋巴瘤复发的CAR T细胞的ZUMA-2试验的良好结果，总缓解率为93％，预期安全性良好。